Dr Desai argued that the sector is undergoing a structural acceleration in how quickly science turns into treatments
Green Vision Centres cut emissions, expand community coverage as partners align on resilient eye health systems
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
It promises fewer injections for vision loss patients
Nearly 12 million people are estimated to be living with glaucoma, making the country one of the worst affected globally
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
